Date:7/26/2012

l will lead to product advancement or partnering; that improvements in the formulation or use of Generx will be commercially practicable, or that Generx could be successfully advanced as a therapeutic in developing markets or that the results of studies in such markets could be used to advance or broaden the regulatory or commercialization activities of Generx in the U.S. or other markets; that the ASPIRE clinical study will be successful or will lead to approval of Generx by the Russian Health Authority for marketing and sales in Russia or lead to approvals in other countries of the Commonwealth of Independent States; that additional clinical evidence regarding the safety and effectiveness of Generx that might be obtained in Russia would be useful for optimizing and broadening commercial development pathways in other industrialized countries; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of opera
'/>"/>

SOURCE Cardium Therapeutics Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function
2. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
3. First targeted and programmable nanomedicine to show clinical antitumor effects published
4. Newly-Published Study Compares SURFAXIN LS™ and CUROSURF® in Well-Established Model of Respiratory Distress Syndrome
5. Edarbyclor (azilsartan medoxomil and chlorthalidone) Head-to-Head Data Published in Hypertension
6. Spiral Flow(TM) Grafts Enhance Patient Outcomes - New Paper Published in the Prestigious Annals of Vascular Surgery
7. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
8. 23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
9. Live Press Briefing on Findings of Biomedical Industry CEO Survey
10. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
11. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI